Isofol Medical

The information in the press release is intended for investors.

The abstract is based on conclusions from the preclinical studies performed in cooperation with Oncosyne AS and Akershus University Hospital in Oslo, Norway, earlier this year. The studies evaluated the effect of arfolitixorin and leucovorin in combination with 5-FU based chemotherapy in patient-derived colorectal cancer tumoroids. The results show that arfolitixorin displays a potent, dose-dependent cytotoxic effect and increased activity in 5-FU-treated tumoroids that, at higher doses, is higher than with today’s standard treatmentleucovorin. The effect was most marked in the tumoroids that were most resistant to 5-FU.

“The conclusions from the preclinical studies support our hypothesis of a suboptimal arfolitixorin dose regime in the phase III clinical trial AGENT. This contributed to not achieving a sufficiently high efficacy to establish superiority to leucovorin in the ITT population. These findings support our conviction that an optimized arfolitixorin dose regimen would provide the opportunity to fairly evaluate the drug candidate’s potential in combination with 5-FU based cancer treatments and support the design of the company’s clinical development plan,” says Dr. Roger Tell, Chief Medical Officer at Isofol.

“This is another study that shows the potential of arfolitixorin and adds to the evidence platform that overall strengthens the prospects of showing promising results in upcoming studies. I am particularly pleased that ENA has classified the results as ‘Late Breaking' and is highlighted as new advances that have the potential to change clinical practice,” says Petter Segelman Lindqvist, CEO Isofol.
ENA 2024 is arranged by the European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute, U.S, (NCI) and American Association for Cancer Research (AACR).

Presenter: Dr. Jarle Bruun, PhD, Chief Executive Officer, Oncosyne AS.
Title: "Dose-dependent cytotoxicity of arfolitixorin, a direct-acting folate, versus leucovorin with 5-fluorouracil in patient-derived colorectal cancer tumoroids (PDTs)”.

Abstract no: 510-LB, Poster no: PB-510

The abstract is published online, https://event.eortc.org/ena2024 (login required) and the poster will be shown in the conference’s Exhibition Hall from 12:00 p.m. on October 23.

For more information, please contact
Isofol Medical AB (publ)
Roger Tell, Chief Medical Officer
E-mail: roger.tell@isofolmedical.com
Phone: +46 (0)760 29 39 11

The information was submitted for publication, through the agency of the contact person set out above, at 11:30 CEST on October 23, 2024.

About Isofol Medical AB (publ)
Isofol Medical AB (publ) aims to raise the quality of life and increase the survival rate for patients with severe forms of cancer. The company’s drug candidate arfolitixorin is being developed with the purpose of increasing the efficacy of standard first-line treatment for several forms of solid tumours, including colorectal cancer. The next step in the clinical development program is currently being prepared based on a new dosage regimen that is expected to optimize arfolitixorin’s efficacy. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.

www.isofolmedical.com